3 ms·
To downvoters: Point 1 was in a Pfizer document first leaked from Japan's government in mid 2021, officially released a year or more later. Point 2 (ish) was
by Izkata 3y ago
To downvoters:
Point 1 was in a Pfizer document first leaked from Japan's government in mid 2021, officially released a year or more later.
Point 2 (ish) was in a footnote in Pfizer's FDA approval notice, there were formulation changes in the inactive ingredients between the EUA and brand version for (IIRC) shelf-life stability. I don't remember details on the exact difference being in there though, and I don't remember differences between the trial and EUA versions (but scaling up can cause this by accident).
- linuxftw 3y agoThanks, I'm not talking about the difference in the EUA and the Approved versions. I'm talking about the clinical trial vs all subsequent versions with regards to how the actual vaccine genetic material was produced. I can't find the reference at the moment, but I believe they used PCR to replicate the mRNA during the trials, and used the bacteria replication for the subsequent versions. Here's a professor giving testimony to his findings: https://www.youtube.com/watch?v=IEWHhrHiiTY https://www.youtube.com/watch?v=IEWHhrHiiTY